-
K.
Moore,
B.
Pothuri,
B.
Monk,
R.
Coleman
(2020)
PARP inhibition in recurrent ovarian cancer.
Clinical advances in hematology & oncology : H&O, 18 10
-
(
BarveM
AdamsN
PlatoL
, et al. Case report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB). Mol Med: Curr Asp. 2017;1:005.)
BarveM
AdamsN
PlatoL
, et al. Case report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB). Mol Med: Curr Asp. 2017;1:005.
BarveM
AdamsN
PlatoL
, et al. Case report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB). Mol Med: Curr Asp. 2017;1:005.,
BarveM
AdamsN
PlatoL
, et al. Case report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB). Mol Med: Curr Asp. 2017;1:005.
-
(
DalencF
GarberisI
FilleronT
, et al. Abstract GS3-02: durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 2020;80:GS3-02-GS3.)
DalencF
GarberisI
FilleronT
, et al. Abstract GS3-02: durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 2020;80:GS3-02-GS3.
DalencF
GarberisI
FilleronT
, et al. Abstract GS3-02: durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 2020;80:GS3-02-GS3.,
DalencF
GarberisI
FilleronT
, et al. Abstract GS3-02: durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 2020;80:GS3-02-GS3.
-
A.
Bardia,
I.
Mayer,
L.
Vahdat,
S.
Tolaney,
S.
Isakoff,
J.
Diamond,
J.
O’Shaughnessy,
R.
Moroose,
A.
Santin,
V.
Abramson,
N.
Shah,
H.
Rugo,
D.
Goldenberg,
A.
Sweidan,
R.
Iannone,
Sarah
Washkowitz,
R.
Sharkey,
W.
Wegener,
K.
Kalinsky
(2019)
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
The New England Journal of Medicine, 380
-
(
LedermannJ
HarterP
GourleyC
, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.24882434)
LedermannJ
HarterP
GourleyC
, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.24882434
LedermannJ
HarterP
GourleyC
, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.24882434,
LedermannJ
HarterP
GourleyC
, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.24882434
-
(
MaplesP
KumarP
YuY
, et al. FANG vaccine: autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. Bioprocess J. 2010;8:4-14.)
MaplesP
KumarP
YuY
, et al. FANG vaccine: autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. Bioprocess J. 2010;8:4-14.
MaplesP
KumarP
YuY
, et al. FANG vaccine: autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. Bioprocess J. 2010;8:4-14.,
MaplesP
KumarP
YuY
, et al. FANG vaccine: autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. Bioprocess J. 2010;8:4-14.
-
R.
Rocconi,
L.
Stanbery,
L.
Silva,
R.
Barrington,
P.
Aaron,
L.
Manning,
S.
Horvath,
G.
Wallraven,
E.
Bognar,
Adam
Walter,
J.
Nemunaitis
(2021)
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
Vaccines, 9
-
E.
Pujade-Lauraine,
K.
Fujiwara,
J.
Ledermann,
A.
Oza,
R.
Kristeleit,
I.
Ray-Coquard,
G.
Richardson,
C.
Sessa,
K.
Yonemori,
Susana
Banerjee,
A.
Leary,
A.
Tinker,
K.
Jung,
R.
Mądry,
S.
Park,
C.
Anderson,
F.
Zohren,
Ross
Stewart,
C.
Wei,
S.
Dychter,
B.
Monk
(2019)
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
Gynecologic Oncology
-
Maurizio
Ghisoli,
M.
Rutledge,
P.
Stephens,
R.
Mennel,
M.
Barve,
Meghan
Manley,
B.
Oliai,
K.
Murphy,
L.
Manning,
B.
Gutierrez,
Priyanka
Rangadass,
A.
Walker,
Zhaohui
Wang,
D.
Rao,
Ned
Adams,
G.
Wallraven,
N.
Senzer,
J.
Nemunaitis
(2017)
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
Journal of pediatric hematology/oncology, 39 4
-
Jonathan
Oh,
M.
Barve,
Carolyn
Matthews,
E.
Koon,
T.
Heffernan,
B.
Fine,
E.
Grosen,
Melanie
Bergman,
Evelyn
Fleming,
L.
Demars,
L.
West,
D.
Spitz,
H.
Goodman,
K.
Hancock,
G.
Wallraven,
Padmasini
Kumar,
E.
Bognar,
L.
Manning,
B.
Pappen,
Ned
Adams,
N.
Senzer,
J.
Nemunaitis
(2016)
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Gynecologic oncology, 143 3
-
M.
Curran,
B.
Glisson
(2019)
New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation.
Annual review of medicine, 70
-
(
NaveO
ElbazM.
Artificial immune system features added to breast cancer clinical data for machine learning (ML) applications. Biosystems. 2021;202:104341.33482276)
NaveO
ElbazM.
Artificial immune system features added to breast cancer clinical data for machine learning (ML) applications. Biosystems. 2021;202:104341.33482276
NaveO
ElbazM.
Artificial immune system features added to breast cancer clinical data for machine learning (ML) applications. Biosystems. 2021;202:104341.33482276,
NaveO
ElbazM.
Artificial immune system features added to breast cancer clinical data for machine learning (ML) applications. Biosystems. 2021;202:104341.33482276
-
(
WadaS
JacksonCM
YoshimuraK
, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.23557194)
WadaS
JacksonCM
YoshimuraK
, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.23557194
WadaS
JacksonCM
YoshimuraK
, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.23557194,
WadaS
JacksonCM
YoshimuraK
, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.23557194
-
(
HerzogTJ
MonkBJ.
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Gynecol Oncol Res Pract. 2017;4:13.28904804)
HerzogTJ
MonkBJ.
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Gynecol Oncol Res Pract. 2017;4:13.28904804
HerzogTJ
MonkBJ.
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Gynecol Oncol Res Pract. 2017;4:13.28904804,
HerzogTJ
MonkBJ.
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Gynecol Oncol Res Pract. 2017;4:13.28904804
-
(
MooreKN
PothuriB
MonkB
ColemanRL.
PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020;18:647-655.33201871)
MooreKN
PothuriB
MonkB
ColemanRL.
PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020;18:647-655.33201871
MooreKN
PothuriB
MonkB
ColemanRL.
PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020;18:647-655.33201871,
MooreKN
PothuriB
MonkB
ColemanRL.
PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020;18:647-655.33201871
-
(
OhJ
BarveM
SenzerN
, et al. Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance. Gynecol Oncol Rep. 2020;34:100648.33364285)
OhJ
BarveM
SenzerN
, et al. Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance. Gynecol Oncol Rep. 2020;34:100648.33364285
OhJ
BarveM
SenzerN
, et al. Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance. Gynecol Oncol Rep. 2020;34:100648.33364285,
OhJ
BarveM
SenzerN
, et al. Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance. Gynecol Oncol Rep. 2020;34:100648.33364285
-
E.
Mittendorf,
A.
Philips,
F.
Meric-Bernstam,
N.
Qiao,
Yun
Wu,
S.
Harrington,
X.
Su,
Ying
Wang,
A.
González-Angulo,
A.
Akcakanat,
A.
Chawla,
M.
Curran,
P.
Hwu,
P.
Sharma,
J.
Litton,
J.
Molldrem,
G.
Alatrash
(2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Cancer Immunology Research, 2
-
A.
González-Angulo,
K.
Timms,
Shuying
Liu,
Huiqin
Chen,
J.
Litton,
J.
Potter,
J.
Lanchbury,
K.
Stemke‐Hale,
B.
Hennessy,
B.
Arun,
G.
Hortobagyi,
K.
Do,
G.
Mills,
F.
Meric-Bernstam
(2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Clinical Cancer Research, 17
-
G.
Mittica,
S.
Genta,
M.
Aglietta,
G.
Valabrega
(2016)
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
International Journal of Molecular Sciences, 17
-
J.
Nemunaitis,
M.
Barve,
D.
Orr,
J.
Kuhn,
M.
Magee,
J.
Lamont,
C.
Bedell,
G.
Wallraven,
B.
Pappen,
A.
Roth,
S.
Horvath,
Derek
Nemunaitis,
Padmasini
Kumar,
P.
Maples,
N.
Senzer
(2014)
Cancer of the Liver
-
(
MalorniL
ShettyPB
De AngelisC
, et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795-804.23124476)
MalorniL
ShettyPB
De AngelisC
, et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795-804.23124476
MalorniL
ShettyPB
De AngelisC
, et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795-804.23124476,
MalorniL
ShettyPB
De AngelisC
, et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795-804.23124476
-
(
ShimokawaM
KogawaT
ShimadaT
, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872-879.29581765)
ShimokawaM
KogawaT
ShimadaT
, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872-879.29581765
ShimokawaM
KogawaT
ShimadaT
, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872-879.29581765,
ShimokawaM
KogawaT
ShimadaT
, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872-879.29581765
-
(
SpriggsDR
BradyMF
VaccarelloL
, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471.17906207)
SpriggsDR
BradyMF
VaccarelloL
, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471.17906207
SpriggsDR
BradyMF
VaccarelloL
, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471.17906207,
SpriggsDR
BradyMF
VaccarelloL
, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471.17906207
-
(
McPhersonK
SteelCM
DixonJM.
ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321:624-628.10977847)
McPhersonK
SteelCM
DixonJM.
ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321:624-628.10977847
McPhersonK
SteelCM
DixonJM.
ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321:624-628.10977847,
McPhersonK
SteelCM
DixonJM.
ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321:624-628.10977847
-
Mph
MD,
MS
MPH,
Mph
MD,
Keelia
Rhoads,
Salina
Chan,
T.
Ms,
R.
Ms,
PhD
MD,
B.
Ms,
P.
Marcom,
Mph
MD
(2013)
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Annals of Surgical Oncology, 20
-
Ophir
Nave,
Miriam
Elbaz
(2021)
Artificial immune system features added to breast cancer clinical data for machine learning (ML) applications
Bio Systems
-
(
SliheetE
RobinsonM
MorandS
, et al. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy [published online ahead of print November
16, 2021]. Cancer Gene Ther. doi:10.1038/s41417-021-00400-x)
SliheetE
RobinsonM
MorandS
, et al. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy [published online ahead of print November
16, 2021]. Cancer Gene Ther. doi:10.1038/s41417-021-00400-x
SliheetE
RobinsonM
MorandS
, et al. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy [published online ahead of print November
16, 2021]. Cancer Gene Ther. doi:10.1038/s41417-021-00400-x,
SliheetE
RobinsonM
MorandS
, et al. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy [published online ahead of print November
16, 2021]. Cancer Gene Ther. doi:10.1038/s41417-021-00400-x
-
(
HolschneiderCH
BerekJS.
Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.10883018)
HolschneiderCH
BerekJS.
Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.10883018
HolschneiderCH
BerekJS.
Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.10883018,
HolschneiderCH
BerekJS.
Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.10883018
-
(
BayraktarS
Gutierrez-BarreraAM
LiuD
, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130:145-153.21830012)
BayraktarS
Gutierrez-BarreraAM
LiuD
, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130:145-153.21830012
BayraktarS
Gutierrez-BarreraAM
LiuD
, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130:145-153.21830012,
BayraktarS
Gutierrez-BarreraAM
LiuD
, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130:145-153.21830012
-
Hichem
Lahouassa,
Waaqo
Daddacha,
H.
Hofmann,
Diana
Ayinde,
Eric
Logue,
Loic
Dragin,
Nicolin
Bloch,
Claire
Maudet,
Matthieu
Bertrand,
T.
Gramberg,
G.
Pancino,
S.
Priet,
B.
Canard,
N.
Laguette,
M.
Benkirane,
C.
Transy,
N.
Landau,
Baek
Kim,
F.
Margottin-Goguet
(2012)
SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates
Nature Immunology, 13
-
S.
Bayraktar,
A.
Gutierrez-Barrera,
Diane
Liu,
T.
Tasbas,
U.
Akar,
J.
Litton,
E.
Lin,
C.
Albarracin,
F.
Meric-Bernstam,
A.
González-Angulo,
G.
Hortobagyi,
B.
Arun
(2011)
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Breast Cancer Research and Treatment, 130
-
(
YadavS
LadkanyR
YadavD
, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229-e1235.29402697)
YadavS
LadkanyR
YadavD
, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229-e1235.29402697
YadavS
LadkanyR
YadavD
, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229-e1235.29402697,
YadavS
LadkanyR
YadavD
, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229-e1235.29402697
-
(
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.25071121)
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.25071121
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.25071121,
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.25071121
-
(
RischHA
McLaughlinJR
ColeDE
, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.11179017)
RischHA
McLaughlinJR
ColeDE
, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.11179017
RischHA
McLaughlinJR
ColeDE
, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.11179017,
RischHA
McLaughlinJR
ColeDE
, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.11179017
-
B.
Monk,
N.
Colombo,
A.
Oza,
K.
Fujiwara,
M.
Birrer,
L.
Randall,
E.
Poddubskaya,
G.
Scambia,
Y.
Shparyk,
M.
Lim,
S.
Bhoola,
J.
Sohn,
K.
Yonemori,
R.
Stewart,
Xiaoxi
Zhang,
J.
Smith,
C.
Linn,
J.
Ledermann
(2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
The Lancet. Oncology
-
Erika
Lampert,
A.
Zimmer,
Michelle
Padget,
A.
Cimino-Mathews,
J.
Nair,
Yingmiao
Liu,
E.
Swisher,
J.
Hodge,
A.
Nixon,
Erin
Nichols,
M.
Bagheri,
Elliott
Levy,
M.
Radke,
S.
Lipkowitz,
C.
Annunziata,
J.
Taube,
S.
Steinberg,
Jung-Min
Lee
(2020)
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Clinical Cancer Research, 26
-
Johnathan
Oh,
M.
Barve,
N.
Senzer,
P.
Aaron,
L.
Manning,
G.
Wallraven,
E.
Bognar,
L.
Stanbery,
S.
Horvath,
Meghan
Manley,
J.
Nemunaitis,
Adam
Walter,
R.
Rocconi
(2020)
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
Gynecologic Oncology Reports, 34
-
(2017)
Case report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB)
-
S.
Wada,
Christopher
Jackson,
K.
Yoshimura,
Hung-Rong
Yen,
D.
Getnet,
T.
Harris,
Monica
Goldberg,
T.
Bruno,
J.
Grosso,
N.
Durham,
G.
Netto,
D.
Pardoll,
C.
Drake
(2013)
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Journal of Translational Medicine, 11
-
(
CreedenJ
OngS
GillmanC
, et al. The role of TGFbeta in clinical cancer response. Clin Oncol Res. 2020;3:1-8.34142081)
CreedenJ
OngS
GillmanC
, et al. The role of TGFbeta in clinical cancer response. Clin Oncol Res. 2020;3:1-8.34142081
CreedenJ
OngS
GillmanC
, et al. The role of TGFbeta in clinical cancer response. Clin Oncol Res. 2020;3:1-8.34142081,
CreedenJ
OngS
GillmanC
, et al. The role of TGFbeta in clinical cancer response. Clin Oncol Res. 2020;3:1-8.34142081
-
S.
Kim,
Maria
Lee,
H.
Kim,
H.
Chung,
Jae-Weon
Kim,
N.
Park,
Y.
Song
(2019)
Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
Journal of Ovarian Research, 12
-
S.
Domchek,
S.
Postel-Vinay,
S.
Im,
Yeon-Hee
Park,
J.
Delord,
A.
Italiano,
J.
Alexandre,
B.
You,
S.
Bastian,
M.
Krebs,
Ding
Wang,
S.
Waqar,
M.
Lanasa,
J.
Rhee,
Hai-Cheng
Gao,
V.
Rocher-Ros,
E.
Jones,
Sakshi
Gulati,
A.
Coenen-Stass,
I.
Kozarewa,
Z.
Lai,
H.
Angell,
L.
Opincar,
P.
Herbolsheimer,
B.
Kaufman
(2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
The Lancet. Oncology
-
(
AbikoK
MatsumuraN
HamanishiJ
, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-1509.25867264)
AbikoK
MatsumuraN
HamanishiJ
, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-1509.25867264
AbikoK
MatsumuraN
HamanishiJ
, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-1509.25867264,
AbikoK
MatsumuraN
HamanishiJ
, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-1509.25867264
-
N.
Senzer,
M.
Barve,
J.
Kuhn,
A.
Melnyk,
P.
Beitsch,
M.
Lazar,
S.
Lifshitz,
M.
Magee,
Jonathan
Oh,
Susan
Mill,
C.
Bedell,
C.
Higgs,
Padmasini
Kumar,
Yang
Yu,
Fabienne
Norvell,
Connor
Phalon,
Nicolas
Taquet,
D.
Rao,
Zhaohui
Wang,
C.
Jay,
B.
Pappen,
G.
Wallraven,
F.
Brunicardi,
D.
Shanahan,
P.
Maples,
J.
Nemunaitis
(2012)
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Molecular therapy : the journal of the American Society of Gene Therapy, 20 3
-
N.
Senzer,
M.
Barve,
J.
Nemunaitis,
J.
Kuhn,
A.
Melnyk,
P.
Beitsch,
M.
Magee,
Jonathan
Oh,
C.
Bedell,
Padmasini
Kumar,
D.
Rao,
B.
Pappen,
G.
Wallraven,
C.
Brunicardi,
P.
Maples,
John
Ne-munaitis
(2013)
Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer
Journal of Vaccines and Vaccination, 4
-
(
DawsonSJ
ProvenzanoE
CaldasC.
Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45:27-4019775602)
DawsonSJ
ProvenzanoE
CaldasC.
Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45:27-4019775602
DawsonSJ
ProvenzanoE
CaldasC.
Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45:27-4019775602,
DawsonSJ
ProvenzanoE
CaldasC.
Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45:27-4019775602
-
E.
Tondini,
Tsolere
Arakelian,
K.
Oosterhuis,
M.
Camps,
Suzanne
Duikeren,
W.
Han,
R.
Arens,
G.
Zondag,
J.
Bergen,
F.
Ossendorp
(2019)
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
Oncoimmunology, 8
-
(
DomchekSM
Postel-VinayS
ImSA
, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.32771088)
DomchekSM
Postel-VinayS
ImSA
, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.32771088
DomchekSM
Postel-VinayS
ImSA
, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.32771088,
DomchekSM
Postel-VinayS
ImSA
, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.32771088
-
Holschneider CH,
Berek JS
(2000)
Ovarian cancer: epidemiology, biology, and prognostic factors
Semin Surg Oncol., 19
-
Sarah-Jane
Dawson,
E.
Provenzano,
Carlos
Caldas
(2009)
Triple negative breast cancers: clinical and prognostic implications.
European journal of cancer, 45 Suppl 1
-
(
ElezabyM
LeesB
MaturenKE
, et al. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology. 2019;291:554-569.31038410)
ElezabyM
LeesB
MaturenKE
, et al. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology. 2019;291:554-569.31038410
ElezabyM
LeesB
MaturenKE
, et al. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology. 2019;291:554-569.31038410,
ElezabyM
LeesB
MaturenKE
, et al. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology. 2019;291:554-569.31038410
-
(
NemunaitisJ
BarveM
OrrD
, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87:21-29.24968881)
NemunaitisJ
BarveM
OrrD
, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87:21-29.24968881
NemunaitisJ
BarveM
OrrD
, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87:21-29.24968881,
NemunaitisJ
BarveM
OrrD
, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87:21-29.24968881
-
R.
Rocconi,
E.
Grosen,
S.
Ghamande,
J.
Chan,
M.
Barve,
Jonathan
Oh,
D.
Tewari,
P.
Morris,
E.
Stevens,
J.
Bottsford-Miller,
M.
Tang,
P.
Aaron,
L.
Stanbery,
S.
Horvath,
G.
Wallraven,
E.
Bognar,
L.
Manning,
J.
Nemunaitis,
D.
Shanahan,
B.
Slomovitz,
T.
Herzog,
B.
Monk,
R.
Coleman
(2020)
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
The Lancet. Oncology, 21 12
-
(
Pujade-LauraineE
LedermannJA
SelleF
, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.28754483)
Pujade-LauraineE
LedermannJA
SelleF
, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.28754483
Pujade-LauraineE
LedermannJA
SelleF
, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.28754483,
Pujade-LauraineE
LedermannJA
SelleF
, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.28754483
-
A.
Hartkopf,
F.
Taran,
M.
Wallwiener,
C.
Walter,
B.
Krämer,
E.
Grischke,
S.
Brucker
(2016)
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care, 11
-
M.
Shimokawa,
T.
Kogawa,
T.
Shimada,
T.
Saito,
H.
Kumagai,
M.
Ohki,
T.
Kaku
(2018)
Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
Journal of Cancer, 9
-
D.
Spriggs,
M.
Brady,
L.
Vaccarello,
D.
Clarke‐Pearson,
R.
Burger,
R.
Mannel,
J.
Boggess,
R.
Lee,
M.
Hanly
(2007)
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
-
J.
Ferlay,
M.
Colombet,
I.
Soerjomataram,
C.
Mathers,
D.
Parkin,
M.
Piñeros,
A.
Znaor,
F.
Bray
(2018)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
International Journal of Cancer, 144
-
(
ZeichnerSB
TerawakiH
GogineniK.
A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25-36.27042088)
ZeichnerSB
TerawakiH
GogineniK.
A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25-36.27042088
ZeichnerSB
TerawakiH
GogineniK.
A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25-36.27042088,
ZeichnerSB
TerawakiH
GogineniK.
A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25-36.27042088
-
Da
Yang,
Sofia
Khan,
Yan
Sun,
K.
Hess,
I.
Shmulevich,
A.
Sood,
Wei
Zhang
(2011)
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
JAMA, 306 14
-
Nemunaitis J,
Barve M,
Orr D,
et al
(2014)
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver
Oncology., 87
-
(
MitticaG
GentaS
AgliettaM
ValabregaG.
Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?
Int J Mol Sci. 2016;17:1169.)
MitticaG
GentaS
AgliettaM
ValabregaG.
Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?
Int J Mol Sci. 2016;17:1169.
MitticaG
GentaS
AgliettaM
ValabregaG.
Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?
Int J Mol Sci. 2016;17:1169.,
MitticaG
GentaS
AgliettaM
ValabregaG.
Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?
Int J Mol Sci. 2016;17:1169.
-
(
AliHR
GlontSE
BlowsFM
, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488-1493.25897014)
AliHR
GlontSE
BlowsFM
, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488-1493.25897014
AliHR
GlontSE
BlowsFM
, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488-1493.25897014,
AliHR
GlontSE
BlowsFM
, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488-1493.25897014
-
M.
Elezaby,
B.
Lees,
K.
Maturen,
L.
Barroilhet,
K.
Wisinski,
S.
Schrager,
L.
Wilke,
E.
Sadowski
(2019)
BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
Radiology, 291 3
-
(
KimSI
LeeM
KimHS
, et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res. 2019;12:40.31064392)
KimSI
LeeM
KimHS
, et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res. 2019;12:40.31064392
KimSI
LeeM
KimHS
, et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res. 2019;12:40.31064392,
KimSI
LeeM
KimHS
, et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res. 2019;12:40.31064392
-
N.
Mcgranahan,
A.
Furness,
R.
Rosenthal,
S.
Ramskov,
R.
Lyngaa,
S.
Saini,
M.
Jamal-Hanjani,
G.
Wilson,
N.
Birkbak,
C.
Hiley,
T.
Watkins,
S.
Shafi,
N.
Murugaesu,
R.
Mitter,
A.
Akarca,
J.
Linares,
T.
Marafioti,
J.
Henry,
E.
Allen,
Diana
Miao,
B.
Schilling,
D.
Schadendorf,
L.
Garraway,
V.
Makarov,
N.
Rizvi,
A.
Snyder,
M.
Hellmann,
T.
Merghoub,
J.
Wolchok,
S.
Shukla,
Catherine
Wu,
K.
Peggs,
T.
Chan,
S.
Hadrup,
S.
Quezada,
C.
Swanton
(2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Science, 351
-
M.
Barve,
J.
Kuhn,
J.
Lamont,
P.
Beitsch,
L.
Manning,
B.
Pappen,
Padmasini
Kumar,
G.
Wallraven,
N.
Senzer,
J.
Nemunaitis
(2016)
Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
, 1
-
Considerations for the JAVELIN OVARIAN 100 study. OncLive
-
(
LampertEJ
ZimmerA
PadgetM
, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26:4268-4279.32398324)
LampertEJ
ZimmerA
PadgetM
, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26:4268-4279.32398324
LampertEJ
ZimmerA
PadgetM
, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26:4268-4279.32398324,
LampertEJ
ZimmerA
PadgetM
, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26:4268-4279.32398324
-
T.
Herzog,
B.
Monk
(2017)
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Gynecologic Oncology Research and Practice, 4
-
Monk BJ,
Herzog TJ,
Krivak TC,
Lewin SN,
Moore KN
Considerations for the JAVELIN OVARIAN 100 study
-
(
SenzerN
BarveM
NemunaitisJ
, et al. Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin. 2013;4:209.)
SenzerN
BarveM
NemunaitisJ
, et al. Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin. 2013;4:209.
SenzerN
BarveM
NemunaitisJ
, et al. Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin. 2013;4:209.,
SenzerN
BarveM
NemunaitisJ
, et al. Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin. 2013;4:209.
-
J.
Cortés,
D.
Cescon,
H.
Rugo,
Z.
Nowecki,
S.
Im,
M.
Yusof,
C.
Gallardo,
O.
Lipatov,
C.
Barrios,
E.
Holgado,
H.
Iwata,
N.
Masuda,
M.
Otero,
E.
Gokmen,
S.
Loi,
Zifang
Guo,
Jingyi
Zhao,
G.
Aktan,
V.
Karantza,
P.
Schmid,
F.
Luis,
Gomez-Abuin
Gonzalo,
Kaen
Diego,
Kowalwszyn
Ruben,
Molina
Matias,
Varela
Mirta,
B.
Sally,
Begbie
Stephen,
Clingan
Philip,
Loi
Sherene,
S.
Dhanusha,
Gombos
Andrea,
Taylor
Donatienne,
Barrios
Carlos,
Brust
Leandro,
C.
Fabiano,
de
Ruffo,
Hegg
Roberto,
L.
Carvalho,
Lissa
Toniazzi,
Rocha
Odebrecht,
Scalabrini
Orlando,
S.
Felipe,
Cescon
David,
C.
Danielle,
Ferrario
Cristiano,
Song
Xinni,
Yu
Joanne,
Acevedo
Alejandro,
G.
Carlos,
Salas
Claudio,
Sanchez
Cesar,
Yanez
Eduardo,
Gomez
Alvaro,
S.
Jesus,
Holeckova
Petra,
Král
Zdeněk,
Melichar
Bohuslav,
Petrakova
Katarina,
Prausová
Jana,
Glavicic
Vesna,
Jakobsen
Erik,
Jensen
Jeanette,
Linnet
Soren,
Lőrincz
Tamás,
Bonnefoi
Herve,
D.
Isabelle,
Goncalves
Anthony,
Hardy-Bessard
Anne-Claire,
Teixeira
Luis,
Blohmer
Jens-Uwe,
Fasching
Peter,
Forstmeyer
Dirk,
H.
Nadia,
Huober
Jens,
Kaczerowsky
Anna,
Kurbacher
Christian,
L.
Sibylle,
Lueftner
Diana,
P-S
Tjoung-Won,
Schumann
Von,
Wimberger
Pauline,
C.
Louis,
K.
Ava,
N.
Roger,
Arkosy
Peter,
Csőszi
Tibor,
K.
Zsuzsanna,
Landherr
László,
Mahr
Karoly,
Rubovszky
Gábor,
C.
John,
Kelly
Catherine,
O.
Seamus,
Cinieri
Saverio,
DAlessio
Antonietta,
Ricevuto
Enrico,
Aruga
Tomoyuki,
Fujii
Takaaki,
Inoue
Kenichi,
Ishikawa
Takashi,
I.
Yoshinori,
Iwasaki
Tsutomu,
I.
Hiroji,
Kosaka
Yoshimasa,
Matsumoto
Koji,
Miyoshi
Yasuo,
Mukai
Hirofumi,
Nakamura
Seigo,
Niikura
Naoki,
Ohta
Shoichiro,
Osaki
Akihiko,
Sagara
Yasuaki,
Suzuki
Eiji,
Takahashi
Masato,
Tanabe
Yuko,
T.
Kenji,
Tsugawa
Koichiro,
Watanabe
Junichiro,
Yamamoto
Naohito,
Yamamoto
Yutaka,
Yamauchi
Teruo,
Bustam
Anita,
Md
Mastura,
Gomez
Angel,
Juarez
Alejandro,
Martinez
Jorge,
Morales-Vasquez
Flavia,
Reyes
Jessica,
Beelen
Karin,
Tjan-Heijnen
Vivianne,
P.
David,
Chmielowska
Ewa,
Nowakowska-Zajdel
Ewa,
Nowecki
Zbigniew,
Radecka
Barbara,
Streb
Joanna,
Szczylik
Cezary,
Tarnawski
Rafal,
Z.
Bogdan,
Arkhipov
Alexander,
Fadeeva
Natalia,
Lipatov
Oleg,
Meshcheryakov
Andrey,
Moiseyenko
Vladimir,
Mukhametshina
Guzel,
Ahn,
Hee,
Im,
Seock-Ah,
L.
Seok,
Park
Hwa,
park
hee,
Bermejo
Begona,
Cortés
Javier,
Cruz
Josefina,
de
Luis,
Garcia
Jose,
Gion
Maria,
H.
Esther,
Zamora
Esther,
Liu
Chien-Ting,
Liu
Mei-Ching,
Huang
Chiun-Sheng,
Tsao
Chao-Jung,
T.
Ling-Ming,
Arslan
Cagatay,
B.
Gul,
C.
Irfan,
Gokmen
Erhan,
Gunduz
Seyda,
Molinas
Nil,
Ozguroglu
Mustafa,
Ozyilkan
Ozgur,
Y.
Sinan,
Chan
Steve,
Graham
Janine,
MacPherson
Iain,
Schmid
Peter,
Turner
Nicholas,
T.
Mark,
Twelves
Christopher,
Wheatley
Duncan,
Adamchuk
Hryhoriy,
Berzoy
Oleksandr,
Bondarenko
Igor,
Kolesnik
Oleksii,
Kolesnik
Olena,
Komisarenko
Hanna,
Kryzhanivska
Anna,
Leshchenko
Iurii,
Nasonova
Alla,
Otchenash
Natalya,
Ponomarova
Olga,
Rusyn
Andrii,
Shevnya
Sergii,
Shparyk
Yaroslav,
Trukhin
Dmytro,
Ursol
Grygorii,
Vynnychenko
Ihor,
Blau
Sibel,
C.
Madhu,
C.
Michael,
C.
Patrick,
Cole
Scott,
D.
Jennifer,
G.
Keerthi,
H.
Jeffrey,
Hoskins
Kent,
I.
William,
Loutfi
Randa,
Lu
Janice,
M.
Raúl,
M.
Susan,
Nanda
Rita,
Oliff
Ira,
Omene
Coral,
P.
Timothy,
Panwalkar
Amit,
P.
Brian,
Rugo
Hope,
Rybalova
Irina,
Schleider
Michael,
Siegel
Robert,
Simon
Michael,
Stampleman
Laura,
Sumrall
Bradley,
Tsai
Michaela,
Valdes-Albini
Frances
(2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet, 396
-
Y.
Drew,
R.
Penson,
D.
O’Malley,
J.
Kim,
S.
Zimmermann,
P.
Roxburgh,
J.
Sohn,
S.
Stemmer,
S.
Bastian,
M.
Ferguson,
B.
You,
S.
Domchek,
H.
Gao,
H.
Angell,
K.
Meyer,
L.
Opincar,
L.
Ottesen,
D.
Koralek,
Susana
Banerjee
(2020)
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Annals of Oncology, 31
-
R.
Rocconi,
E.
Stevens,
J.
Bottsford-Miller,
S.
Ghamande,
J.
Elder,
L.
Demars,
A.
Munkarah,
P.
Aaron,
L.
Stanbery,
G.
Wallraven,
E.
Bognar,
Meghan
Manley,
S.
Horvath,
L.
Manning,
Adam
Walter,
E.
Galanis,
T.
Herzog,
B.
Monk,
R.
Coleman,
J.
Nemunaitis
(2021)
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Cancer Gene Therapy, 29
-
Huimei
Yi,
Ying
Li,
Yuan
Tan,
Shujun
Fu,
Faqing
Tang,
Xiyun
Deng
(2021)
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
Frontiers in Oncology, 11
-
M.
Mirza,
B.
Monk,
J.
Herrstedt,
A.
Oza,
S.
Mahner,
A.
Redondo,
M.
Fabbro,
J.
Ledermann,
D.
Lorusso,
I.
Vergote,
N.
Ben-Baruch,
C.
Marth,
R.
Mądry,
R.
Christensen,
J.
Berek,
A.
Dørum,
A.
Tinker,
A.
Bois,
A.
González-Martín,
P.
Follana,
B.
Benigno,
P.
Rosenberg,
L.
Gilbert,
B.
Rimel,
J.
Buscema,
J.
Balser,
S.
Agarwal,
U.
Matulonis
(2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England journal of medicine, 375 22
-
S.
Zeichner,
Hiromi
Terawaki,
K.
Gogineni
(2016)
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Breast Cancer : Basic and Clinical Research, 10
-
(
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.33882206)
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.33882206
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.33882206,
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.33882206
-
(
WangX
WangS-S
HuangH
, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50-58.33300950)
WangX
WangS-S
HuangH
, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50-58.33300950
WangX
WangS-S
HuangH
, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50-58.33300950,
WangX
WangS-S
HuangH
, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50-58.33300950
-
(
RocconiRP
StanberyL
Madeirada
SilvaL
, et al. Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer. Vaccines (Basel). 2021;9:894.34452019)
RocconiRP
StanberyL
Madeirada
SilvaL
, et al. Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer. Vaccines (Basel). 2021;9:894.34452019
RocconiRP
StanberyL
Madeirada
SilvaL
, et al. Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer. Vaccines (Basel). 2021;9:894.34452019,
RocconiRP
StanberyL
Madeirada
SilvaL
, et al. Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer. Vaccines (Basel). 2021;9:894.34452019
-
(
HartkopfAD
TaranFA
WallwienerM
, et al. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel). 2016;11:385-390.28228704)
HartkopfAD
TaranFA
WallwienerM
, et al. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel). 2016;11:385-390.28228704
HartkopfAD
TaranFA
WallwienerM
, et al. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel). 2016;11:385-390.28228704,
HartkopfAD
TaranFA
WallwienerM
, et al. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel). 2016;11:385-390.28228704
-
Elyssa
Sliheet,
Molly
Robinson,
Susan
Morand,
Khalil
Choucair,
D.
Willoughby,
L.
Stanbery,
P.
Aaron,
E.
Bognar,
J.
Nemunaitis
(2021)
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
Cancer Gene Therapy, 29
-
L.
Malorni,
P.
Shetty,
C.
Angelis,
S.
Hilsenbeck,
M.
Rimawi,
R.
Elledge,
C.
Osborne,
S.
Placido,
G.
Arpino
(2012)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
Breast Cancer Research and Treatment, 136
-
C.
Perou,
T.
Sørlie,
M.
Eisen,
M.
Rijn,
S.
Jeffrey,
Christian
Rees,
J.
Pollack,
D.
Ross,
H.
Johnsen,
L.
Akslen,
Ø.
Fluge,
Alexander
Pergamenschikov,
Cheryl
Williams,
Shirley
Zhu,
P.
Lønning,
A.
Børresen-Dale,
P.
Brown,
D.
Botstein
(2000)
Molecular portraits of human breast tumours
Nature, 406
-
P.
Maples,
Padmasini
Kumar,
Yang
Yu,
Zhaohui
Wang,
C.
Jay,
B.
Pappen,
D.
Rao,
J.
Kuhn,
J.
Nemunaitis,
N.
Senzer
(2010)
FANG Vaccine : Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin
-
Maurizio
Ghisoli,
M.
Barve,
R.
Schneider,
R.
Mennel,
C.
Lenarsky,
G.
Wallraven,
B.
Pappen,
J.
Lanoue,
Padmasini
Kumar,
Derek
Nemunaitis,
A.
Roth,
J.
Nemunaitis,
S.
Whiting,
N.
Senzer,
F.
Fletcher,
J.
Nemunaitis
(2015)
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Molecular Therapy, 23
-
Xi
Wang,
Shusen
Wang,
Heng
Huang,
L.
Cai,
Li
Zhao,
Roujun
Peng,
Ying
Lin,
Jun
Tang,
J.
Zeng,
Le-hong
Zhang,
Y.
Ke,
Xianming
Wang,
Xin-Mei
Liu,
Qianjun
Chen,
Anqin
Zhang,
Fei
Xu,
X.
Bi,
Jiajia
Huang,
Jibin
Li,
D.
Pang,
C.
Xue,
Yan-Xia
Shi,
Zhen-Yu
He,
Huan-xin
Lin,
X.
An,
W.
Xia,
Ye
Cao,
Ying
Guo,
Yanhong
Su,
X.
Hua,
Xinyue
Wang,
R.
Hong,
K.
Jiang,
Chenge
Song,
Zhangzan
Huang,
W.
Shi,
Y.
Zhong,
Zhongyu
Yuan
(2020)
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
JAMA
-
Yinan
Dong,
Qian
Sun,
Xinwei
Zhang
(2016)
PD-1 and its ligands are important immune checkpoints in cancer
Oncotarget, 8
-
H.
Ali,
Silvia-Elena
Glont,
F.
Blows,
E.
Provenzano,
S.
Dawson,
Bin
Liu,
L.
Hiller,
J.
Dunn,
C.
Poole,
S.
Bowden,
H.
Earl,
P.
Pharoah,
C.
Caldas
(2015)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 7
-
(
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.33278935)
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.33278935
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.33278935,
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.33278935
-
(
YiH
LiY
TanY
FuS
TangF
DengX.
Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139.34094935)
YiH
LiY
TanY
FuS
TangF
DengX.
Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139.34094935
YiH
LiY
TanY
FuS
TangF
DengX.
Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139.34094935,
YiH
LiY
TanY
FuS
TangF
DengX.
Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139.34094935
-
F.
Dalenc,
I.
Garberis,
T.
Filleron,
A.
Lusque,
T.
Bachelot,
M.
Arnedos,
M.
Campone,
M.
Sablin,
H.
Bonnefoi,
M.
Jimenez,
Jacquet
Alexandra,
F.
André
(2020)
Abstract GS3-02: Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIR02-IMMUNO
Cancer Research, 80
-
(
GhisoliM
BarveM
SchneiderR
, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015;23:1103-1109.25917459)
GhisoliM
BarveM
SchneiderR
, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015;23:1103-1109.25917459
GhisoliM
BarveM
SchneiderR
, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015;23:1103-1109.25917459,
GhisoliM
BarveM
SchneiderR
, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015;23:1103-1109.25917459
-
A.
Roebroek,
L.
Umans,
I.
Pauli,
Elizabeth
Robertson,
F.
Leuven,
W.
Ven,
Daniel
Constam
(1998)
Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin.
Development, 125 24
-
(
GreenupR
BuchananA
LorizioW
, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.23975317)
GreenupR
BuchananA
LorizioW
, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.23975317
GreenupR
BuchananA
LorizioW
, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.23975317,
GreenupR
BuchananA
LorizioW
, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.23975317
-
(
KarakiS
AnsonM
TranT
, et al. Is there still room for cancer vaccines at the era of checkpoint inhibitors. Vaccines (Basel). 2016;4:37.)
KarakiS
AnsonM
TranT
, et al. Is there still room for cancer vaccines at the era of checkpoint inhibitors. Vaccines (Basel). 2016;4:37.
KarakiS
AnsonM
TranT
, et al. Is there still room for cancer vaccines at the era of checkpoint inhibitors. Vaccines (Basel). 2016;4:37.,
KarakiS
AnsonM
TranT
, et al. Is there still room for cancer vaccines at the era of checkpoint inhibitors. Vaccines (Basel). 2016;4:37.
-
(
Gonzalez-AnguloAM
TimmsKM
LiuS
, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089.21233401)
Gonzalez-AnguloAM
TimmsKM
LiuS
, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089.21233401
Gonzalez-AnguloAM
TimmsKM
LiuS
, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089.21233401,
Gonzalez-AnguloAM
TimmsKM
LiuS
, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089.21233401
-
(
DongY
SunQ
ZhangX.
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-2186.27974689)
DongY
SunQ
ZhangX.
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-2186.27974689
DongY
SunQ
ZhangX.
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-2186.27974689,
DongY
SunQ
ZhangX.
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-2186.27974689
-
(
Pujade-LauraineaE
FujiwarabK
LedermanncJA
, et al., Eds. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Paper presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019; Honolulu, HI.)
Pujade-LauraineaE
FujiwarabK
LedermanncJA
, et al., Eds. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Paper presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019; Honolulu, HI.
Pujade-LauraineaE
FujiwarabK
LedermanncJA
, et al., Eds. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Paper presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019; Honolulu, HI.,
Pujade-LauraineaE
FujiwarabK
LedermanncJA
, et al., Eds. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Paper presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019; Honolulu, HI.
-
(
YangD
KhanS
SunY
, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306:1557-1565.21990299)
YangD
KhanS
SunY
, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306:1557-1565.21990299
YangD
KhanS
SunY
, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306:1557-1565.21990299,
YangD
KhanS
SunY
, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306:1557-1565.21990299
-
(
DrewY
PensonRT
O’MalleyDM
, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31:S551-S589.)
DrewY
PensonRT
O’MalleyDM
, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31:S551-S589.
DrewY
PensonRT
O’MalleyDM
, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31:S551-S589.,
DrewY
PensonRT
O’MalleyDM
, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31:S551-S589.
-
C.
Holschneider,
J.
Berek
(2000)
Ovarian cancer: epidemiology, biology, and prognostic factors.
Seminars in surgical oncology, 19 1
-
(
PerouCM
SorlieT
EisenMB
, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.10963602)
PerouCM
SorlieT
EisenMB
, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.10963602
PerouCM
SorlieT
EisenMB
, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.10963602,
PerouCM
SorlieT
EisenMB
, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.10963602
-
S.
Yadav,
Rand
Ladkany,
D.
Yadav,
O.
Alhalabi,
Sinan
Khaddam,
D.
Isaac,
P.
Cardenas,
D.
Zakalik
(2017)
Impact of BRCA Mutation Status on Survival of Women With Triple‐negative Breast Cancer
Clinical Breast Cancer, 18
-
(
LahouassaH
DaddachaW
HofmannH
, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13:223-228.22327569)
LahouassaH
DaddachaW
HofmannH
, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13:223-228.22327569
LahouassaH
DaddachaW
HofmannH
, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13:223-228.22327569,
LahouassaH
DaddachaW
HofmannH
, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13:223-228.22327569
-
S.
Karaki,
M.
Anson,
T.
Tran,
D.
Giusti,
C.
Blanc,
S.
Oudard,
E.
Tartour
(2016)
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Vaccines, 4
-
S.
Adams,
R.
Gray,
S.
Demaria,
L.
Goldstein,
E.
Perez,
L.
Shulman,
S.
Martino,
Molin
Wang,
V.
Jones,
T.
Saphner,
A.
Wolff,
W.
Wood,
N.
Davidson,
G.
Sledge,
J.
Sparano,
S.
Badve
(2014)
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 27
-
(
CurranMA
GlissonBS.
New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Annu Rev Med. 2019;70:409-424.30379596)
CurranMA
GlissonBS.
New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Annu Rev Med. 2019;70:409-424.30379596
CurranMA
GlissonBS.
New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Annu Rev Med. 2019;70:409-424.30379596,
CurranMA
GlissonBS.
New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Annu Rev Med. 2019;70:409-424.30379596
-
(
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.31194225)
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.31194225
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.31194225,
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.31194225
-
(
RoebroekAJ
UmansL
PauliIG
, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development. 1998;125:4863-4876.9811571)
RoebroekAJ
UmansL
PauliIG
, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development. 1998;125:4863-4876.9811571
RoebroekAJ
UmansL
PauliIG
, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development. 1998;125:4863-4876.9811571,
RoebroekAJ
UmansL
PauliIG
, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development. 1998;125:4863-4876.9811571
-
J.
Ledermann,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
Clare
Scott,
W.
Meier,
R.
Shapira-Frommer,
T.
Safra,
D.
Matei,
A.
Fielding,
S.
Spencer,
B.
Dougherty,
M.
Orr,
D.
Hodgson,
J.
Barrett,
U.
Matulonis
(2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
The Lancet. Oncology, 15 8
-
(2020)
The role of TGFbeta in clinical cancer response
-
(
FerlayJ
ColombetM
SoerjomataramI
, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.30350310)
FerlayJ
ColombetM
SoerjomataramI
, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.30350310
FerlayJ
ColombetM
SoerjomataramI
, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.30350310,
FerlayJ
ColombetM
SoerjomataramI
, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.30350310
-
K.
McPherson,
C.
Steel,
J.
Dixon
(2000)
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics.
BMJ, 321 7261
-
(
TondiniE
ArakelianT
OosterhuisK
, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8:1652539.31646082)
TondiniE
ArakelianT
OosterhuisK
, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8:1652539.31646082
TondiniE
ArakelianT
OosterhuisK
, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8:1652539.31646082,
TondiniE
ArakelianT
OosterhuisK
, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8:1652539.31646082
-
(
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-370.24764583)
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-370.24764583
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-370.24764583,
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-370.24764583
-
S.
Vinayak,
S.
Tolaney,
L.
Schwartzberg,
M.
Mita,
G.
McCann,
A.
Tan,
Andrea
Wahner-Hendrickson,
A.
Forero,
C.
Anders,
G.
Wulf,
P.
Dillon,
F.
Lynce,
C.
Zarwan,
J.
Erban,
Yinghui
Zhou,
N.
Buerstatte,
J.
Graham,
S.
Arora,
B.
Dezube,
M.
Telli
(2019)
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
JAMA oncology
-
(
MirzaMR
MonkBJ
HerrstedtJ
, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.27717299)
MirzaMR
MonkBJ
HerrstedtJ
, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.27717299
MirzaMR
MonkBJ
HerrstedtJ
, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.27717299,
MirzaMR
MonkBJ
HerrstedtJ
, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.27717299
-
K.
Abiko,
N.
Matsumura,
J.
Hamanishi,
N.
Horikawa,
R.
Murakami,
K.
Yamaguchi,
Y.
Yoshioka,
T.
Baba,
I.
Konishi,
M.
Mandai
(2015)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
British Journal of Cancer, 112
-
H.
Risch,
J.
McLaughlin,
D.
Cole,
B.
Rosen,
L.
Bradley,
E.
Kwan,
E.
Jack,
D.
Vesprini,
G.
Kuperstein,
J.
Abrahamson,
I.
Fan,
B.
Wong,
S.
Narod
(2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
American journal of human genetics, 68 3
-
(
McGranahanN
FurnessAJ
RosenthalR
, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.26940869)
McGranahanN
FurnessAJ
RosenthalR
, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.26940869
McGranahanN
FurnessAJ
RosenthalR
, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.26940869,
McGranahanN
FurnessAJ
RosenthalR
, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.26940869
-
R.
Rocconi,
B.
Monk,
Adam
Walter,
T.
Herzog,
E.
Galanis,
L.
Manning,
E.
Bognar,
G.
Wallraven,
L.
Stanbery,
P.
Aaron,
N.
Senzer,
R.
Coleman,
J.
Nemunaitis
(2021)
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecologic oncology
-
(
MonkBJ
HerzogTJ
KrivakTC
LewinSN
MooreKN.
Considerations for the JAVELIN OVARIAN 100 study. OncLive. May
27, 2020. https://www.onclive.com/view/considerations-for-the-javelin-ovarian-100-study)
MonkBJ
HerzogTJ
KrivakTC
LewinSN
MooreKN.
Considerations for the JAVELIN OVARIAN 100 study. OncLive. May
27, 2020. https://www.onclive.com/view/considerations-for-the-javelin-ovarian-100-study
MonkBJ
HerzogTJ
KrivakTC
LewinSN
MooreKN.
Considerations for the JAVELIN OVARIAN 100 study. OncLive. May
27, 2020. https://www.onclive.com/view/considerations-for-the-javelin-ovarian-100-study,
MonkBJ
HerzogTJ
KrivakTC
LewinSN
MooreKN.
Considerations for the JAVELIN OVARIAN 100 study. OncLive. May
27, 2020. https://www.onclive.com/view/considerations-for-the-javelin-ovarian-100-study
-
A.
Bardia,
S.
Hurvitz,
S.
Tolaney,
D.
Loirat,
K.
Punie,
Mafalda
Oliveira,
A.
Brufsky,
S.
Sardesai,
K.
Kalinsky,
A.
Zelnak,
R.
Weaver,
T.
Traina,
F.
Dalenc,
P.
Aftimos,
F.
Lynce,
S.
Diab,
J.
Cortés,
J.
O’Shaughnessy,
V.
Diéras,
C.
Ferrario,
P.
Schmid,
L.
Carey,
L.
Gianni,
M.
Piccart,
S.
Loibl,
D.
Goldenberg,
Q.
Hong,
M.
Olivo,
L.
Itri,
H.
Rugo
(2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
The New England journal of medicine, 384 16
-
E.
Pujade-Lauraine,
J.
Ledermann,
F.
Selle,
V.
Gebski,
R.
Penson,
A.
Oza,
J.
Korach,
T.
Huzarski,
A.
Poveda,
S.
Pignata,
M.
Friedlander,
N.
Colombo,
P.
Harter,
K.
Fujiwara,
I.
Ray-Coquard,
Susana
Banerjee,
Joyce
Liu,
E.
Lowe,
R.
Bloomfield,
P.
Pautier
(2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 18 9